Taken as a whole, these observations support the notion that TRAP1 quality control and antiapoptotic protein network is a potential molecular target for anticancer therapy and that BRAF-addicted tumors are a suitable and attractive tumor cell model to evaluate this novel therapeutic strategy. The gene discussed is BRAF; the disease is neoplasm.